Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The company's pipeline leverages its proprietary Durasert® and Verisome® sustained-release drug delivery technologies. Key commercial products include YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU® (dexamethasone intraocular suspension) 9% for the treatment of post-operative inflammation. Their lead pipeline candidate, EYP-1901, is an investigational sustained delivery maintenance treatment for wet age-related macular degeneration (wet AMD) and non-proliferative diabetic retinopathy.
The headquarters serves as the central hub for EyePoint Pharmaceuticals' research and development, clinical operations, commercial strategy, and corporate administration.
The Watertown facility is strategically located within the Greater Boston life sciences cluster, providing access to talent and research collaborations. The facilities likely include modern office spaces and may have or be near specialized laboratory environments suitable for pharmaceutical development.
EyePoint Pharmaceuticals fosters a science-driven, patient-focused, and collaborative work environment. The culture emphasizes innovation, integrity, and a commitment to addressing unmet medical needs in ophthalmology.
The headquarters is pivotal for driving the company's mission, coordinating global (or multi-regional) clinical trials, managing product commercialization, and advancing its pipeline of ophthalmic therapies.
EyePoint Pharmaceuticals' primary operations, including R&D and commercial activities, are centered in the United States. However, their products, such as YUTIQ®, have regulatory approvals and are marketed in other regions (e.g., Europe) through partnerships and licensing agreements. Their clinical trials for pipeline candidates may also involve international sites to ensure diverse patient populations and meet global regulatory standards.
120 Water Street
Watertown
Massachusetts
USA
Address: Not Applicable (Remote/Field-based roles)
These teams are responsible for engaging with healthcare professionals, providing medical and product information, supporting clinical trial sites, and driving commercial adoption of EyePoint's therapies nationwide.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, EyePoint Pharmaceuticals' leadership includes:
EyePoint Pharmaceuticals has been backed by several prominent investors over the years, including:
Over the past year, EyePoint Pharmaceuticals has made strategic additions to its leadership team to support its ongoing clinical development and commercial efforts. Notably, Michael Pine was appointed as Chief Legal Officer.
Discover the tools EyePoint Pharmaceuticals uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
EyePoint Pharmaceuticals commonly uses the email format combining the first initial of an employee's first name with their full last name. Other variations might exist but this is a prevalent structure.
[first_initial][last]@eyepointpharma.com
Format
jdoe@eyepointpharma.com
Example
80%
Success rate
EyePoint Pharmaceuticals Investor Relations • May 9, 2024
EyePoint Pharmaceuticals announced its financial results for the first quarter of 2024, providing updates on its commercial products and the advancement of its clinical pipeline, particularly EYP-1901 for wet AMD and other retinal diseases....more
EyePoint Pharmaceuticals Investor Relations • March 7, 2024
The company reported its Q4 and full-year 2023 financials, highlighting progress in its EYP-1901 program and continued commercial performance of YUTIQ® and DEXYCU®....more
EyePoint Pharmaceuticals Investor Relations • December 5, 2023
EyePoint shared positive topline results from the DAVIO 2 Phase 2 trial of EYP-1901, showing promising efficacy with a potential six-month treatment interval for wet age-related macular degeneration, alongside a favorable safety profile....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including EyePoint Pharmaceuticals, are just a search away.